Pamidronate (sodium salt) – 250 mg

Brand:
Cayman
CAS:
57248-88-1
Storage:
-20
UN-No:
Non-Hazardous - /

Pamidronate is an amino bisphosphonate that inhibits farnesyl pyrophosphate (FPP) synthase (IC50s = 0.85 and 0.20 µM in J774 cells and for human recombinant FPP synthase, respectively).{41320} In rats, it inhibits bone resorption when used at doses of 16 µmol/kg per day, impairs long bone growth at ≥40 µmol/kg per day, and has anti-hypercalcemic effects in a rat hypercalcemia model.{41318,41317} At high concentrations, pamidronate induces activation of matrix metalloproteinase-2 (MMP-2), NF-κB, and caspase-3, leading to cell death, which can be prevented by activated protein C.{41319} Formulations containing pamidronate have been used to treat hypercalcemia, Paget’s disease, metastatic bone disease, and multiple myeloma.  

 

Available on backorder

SKU: 23699 - 250 mg Category:

Description

An FPP synthase inhibitor (IC50s = 0.85 and 0.20 µM in J774 cells and for human recombinant FPP synthase, respectively); inhibits bone resorption in rats when used at doses of 16 µmol/kg per day and impairs long bone growth at ≥40 µmol/kg per day; has anti-hypercalcemic effects in a rat hypercalcemia model; high concentrations induce activation of MMP-2, NF-κB, and caspase-3, leading to cell death


Formal name: P,P’-(3-amino-1-hydroxypropylidene)bis-phosphonic acid, disodium salt

Synonyms:  APD|CGP 23339A|Pamidronic Acid

Molecular weight: 279

CAS: 57248-88-1

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Sterol Biosynthesis||Research Area|Cancer|Cell Migration & Metastasis||Research Area|Endocrinology & Metabolism|Bone Growth & Remodeling